Commissioning for rare diseases: view from the frontline.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 16254306.
- Also identified by PMC identifier 1273463.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Deciding whether to fund treatments that do good one by one tends to lead to a positive decision. However, this can cause wider harmful effects, as West Midlands' experience in the funding of enzyme replacement therapy for lysosomal storage diseases shows
Medical subject headings
- Orphan Drug Production
- Rare Diseases